Trial reportAnnals of the rheumatic diseases2006
Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36.
Trial report in Annals of the rheumatic diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Nonspecific adverse events in knee osteoarthritis clinical trials: a systematic review.PloS one · 2014Pooled it
- EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).Annals of the rheumatic diseases · 2007Guideline
- EULAR recommendations for knee and hip osteoarthritis: a critique of the methodology.British journal of sports medicine · 2006Pooled it
- A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis.Clinical rheumatology · 2011Trial
- Advances in heterogeneity and classification of osteoarthritis.Bone research · 2026Review
- Influence of pulsed electromagnetic field (PEMF) therapy on osteoarthritis in dogs.BMC veterinary research · 2025Article
- Changes in health-related quality of life over the first three months of medical marijuana use.Journal of cannabis research · 2024Article
- Use of prescribed analgesics before and after exercise therapy and patient education in patients with knee or hip osteoarthritis.Rheumatology international · 2024Article
- Acupuncture in the Treatment of a Series of Patients with Chronic Pain Associated with Hip Osteoarthritis.Revista brasileira de ortopedia · 2023Article
- Article
- Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?Clinical medicine insights. Arthritis and musculoskeletal disorders · 2021Article
- Article
- Is Lutikizumab, an Anti-Interleukin-1BioMed research international · 2020Article
- Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.Nature reviews. Rheumatology · 2016Review
- Esterase-activated release of naproxen from supramolecular nanofibres.Chemical communications (Cambridge, England) · 2014Article
- Effects of Meditation on Symptoms of Knee Osteoarthritis.Alternative & complementary therapies : a new bimonthly publication for health care practitioners · 2013Article
- Osteoarthritis subpopulations and implications for clinical trial design.Arthritis research & therapy · 2011Review
- Epidemiology of hip and knee pain in a community based sample of Italian persons aged 65 and older.Osteoarthritis and cartilage · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the improvement of hip and knee osteoarthritis during treatment with naproxen.
methodsMen and women aged 40 to 75 years with symptomatic osteoarthritis of the knee or hip of at least three months' duration participated in a six week placebo controlled, double blind study with naproxen 500 mg twice daily as one treatment arm. Naproxen was given to 403 patients (280 knee, 123 hip) and placebo to 108 patients (75 knee, 33 hip). WOMAC (Western Ontario and McMaster Universities osteoarthritis index) 3.1 visual analogue scale and SF-36 (36 item short form health survey) were used to assess response to treatment between baseline and week 6.
resultsThere were no differences at baseline between knee and hip osteoarthritis for any of the WOMAC subscales or SF-36 domains. Improvement was between 4 and 7 mm greater for knee than for hip for all WOMAC subscales (pain, delta = 4.7 mm (p = 0.03); stiffness, delta = 6.6 mm (p = 0.004); function, delta = 4.8 mm (p = 0.06)). Effect size was about 0.8 for all WOMAC subscales for the knee and between 0.5 and 0.6 for the hip. Knee patients treated with naproxen improved 4.6 (p = 0.033) more than hip patients for SF-36 bodily pain and 10.3 (p = 0.014) more for SF-36 role-physical.
conclusionsPatients with knee osteoarthritis improved more with naproxen treatment than patients with hip osteoarthritis, as monitored by WOMAC and the SF-36 domains bodily pain and role-physical. These findings warrant further investigation and strongly suggest that efficacy of treatment of osteoarthritis of knee and hip should be evaluated separately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.